Get the Stockscreener App
7.57
2.44%
0.18
Biocryst Pharmaceuticals Inc stock is traded at $7.57, with a volume of 4.79M.
It is up +2.44% in the last 24 hours and up +3.70% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$7.39
Open:
$7.25
24h Volume:
4.79M
Relative Volume:
2.42
Market Cap:
$1.57B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-6.056
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
+0.53%
1M Performance:
+3.70%
6M Performance:
+23.09%
1Y Performance:
+34.22%
1-Day Range:
$7.25
$7.60
1-Week Range:
$7.1501
$7.62
52-Week Range:
$4.03
$8.88
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Industry
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.57 | 1.57B | 331.41M | -226.54M | -97.31M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
107,820 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Acquired by Wellington Management Group LLP - MarketBeat
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
XTX Topco Ltd Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
State Street Corp Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
Biocryst Pharmaceuticals director Nancy Hutson sells $52,780 in stock - Investing.com
Verition Fund Management LLC Sells 102,839 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy - Seeking Alpha
Charles Schwab Investment Management Inc. Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Two Sigma Advisers LP Acquires 261,500 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
The Manufacturers Life Insurance Company Has $2.27 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Jacobs Levy Equity Management Inc. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Yahoo Finance
BNP Paribas Financial Markets Has $3.78 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals Awards Stock Options, RSUs to New Employees in Inducement Package - StockTitan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts - MarketBeat
Cinctive Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 7th Largest Position - MarketBeat
Fisher Asset Management LLC Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
(BCRX) On The My Stocks Page - Stock Traders Daily
Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Simply Wall St
Algert Global LLC Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $5.19 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Principal Financial Group Inc. Purchases 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Orladeyo now available to treat HAE patients in Ireland - Angioedema News Today
Hereditary Angioedema Therapeutics Market Report Outlines - openPR
Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland - StockTitan
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst's SWOT analysis: stock outlook amid orladeyo success, pipeline shifts - Investing.com UK
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Clearside's Eye Treatment Platform Gains Momentum with Major Santen Partnership in China - StockTitan
Ionis Looks Ahead To Commercializing Its Own Products - Citeline
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):